- (2007): Jhaveri K+, Breast Cancer Res Treat 106(3), 315 (3 cases)
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2016): Krasenska M, Klin Onkol (Czech) 29(Suppl 3), 39
- (2015): Yeruva SL+, Case Rep Hematol Jun, Epub
Adverse reactions attributed to entire drug class 'Aromatase inhibitor'
Please login to view adverse reactions.
- (2016): Karatas F+, Springerplus 5, 585 [REVIEW]
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2016): Krasenska M, Klin Onkol (Czech) 29(Suppl 3), 39
- (2016): Krasenska M, Klin Onkol (Czech) 29(Suppl 3), 39
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4651–47% [REVIEW]
- (2018): Nahm N+, Asia Pac J Clin Oncol Jan, Epub ahead of print [REVIEW]
- (2016): Krasenska M, Klin Onkol 29(Suppl 3), 39
- (2016): Lombard JM+, Support Care Cancer 24(5), 2139
- (2016): Sahin S+, J BUON 21(1), 17
- (2015): Yeruva SL+, Case Rep Hematol Jun, Epub
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4657–33% [REVIEW]
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2016): Krasenska M, Klin Onkol (Czech) 29(Suppl 3), 39
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4657–33% [REVIEW]
- (2015): Yeruva SL+, Case Rep Hematol Jun, Epub
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2016): Ryden L+, Breast 26, 106 [REVIEW]
Myalgia/Myositis/Myopathy/Myotoxicity
- (2021): Andrikopoulou A+, Cancers (Basel) 13(3), 4652–24% [REVIEW]
- (2016): Krasenska M, Klin Onkol (Czech) 29(Suppl 3), 39
- (2016): Lombard JM+, Support Care Cancer 24(5), 2139
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
- (2015): Yeruva SL+, Case Rep Hematol Jun, Epub
- (2016): Knobloch K, Adv Exp Med Biol 920, 229
- (2013): Turaka K+, Clin Experiment Ophthalmol 41(3), 23910%
- (2016): Gradishar WJ, Cancer Manag Res 8, 85 [REVIEW]
